Avadel Pharmaceuticals plc (NASDAQ:AVDL) is now up 33.73% compared to a 12-month low of $1.69. We have seen the price to move -10.67% lower and get settled at $2.26 on 02/08/2019. At recent session, it appeared stuck in a range of $2.22 to $2.4854. This company shares are 242.92% off its target price of $7.75 and the current market capitalization stands at $93.61M. The recent change has given its price a -15.68% deficit over SMA 50 and -77.35% deficit over its 52-week high. The stock witnessed -21.25% declines, -24.41% declines and -57.56% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AVDL’s volatility during a week at 14.41% and during a month it has been found around 10.63%.

Avadel Pharmaceuticals plc (AVDL) Top Holders

Institutional investors currently hold around $43 million or 58.6% in AVDL stock. Look at its top three institutional owners. Brandes Investment Partners, Lp owns $14.32 million in Avadel Pharmaceuticals plc, which represents roughly 15.3% of the company’s market cap and approximately 33.3% of the institutional ownership. Similar statistics are true for the second largest owner, Broadfin Capital, Llc, which owns 2,792,773 shares of the stock are valued at $6.31 million. The third largest holder is Deerfield Management Company, L.P. (Series C), which currently holds $6.15 million worth of this stock and that ownership represents nearly 6.57% of its market capitalization.

Avadel Pharmaceuticals plc 13F Filings

At the end of September reporting period, 14 institutional holders increased their position in Avadel Pharmaceuticals plc (NASDAQ:AVDL) by some 2,165,428 shares, 44 decreased positions by 3,032,724 and 21 held positions by 13,788,288. That puts total institutional holdings at 18,986,440 shares, according to SEC filings. The stock grabbed 4 new institutional investments totaling 355,861 shares while 20 institutional investors sold out their entire positions totaling 1,094,325 shares.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Insider Trades

Multiple company employees have indulged in significant insider trading. Avadel Pharmaceuticals plc disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Hatten Sandra L has sold 3,173 shares of Avadel Pharmaceuticals plc (AVDL) in trading session dated Dec. 14, 2018. These shares are worth $8,186 and were traded at $2.58 each. The SEC filing shows that Gusky David P performed a sale of 617 shares. The Controller & CAO disposed these shares by way of transaction on Dec. 14, 2018. The company’s shares were given away at $2.68 per share worth to an income of some $1,654 on account of Gusky David P.

, Kanan Michael F, sold 8,429 common shares of Avadel Pharmaceuticals plc (AVDL) in the open market. In a transaction dated Dec. 14, 2018, the shares were put up for sale at an average price of $2.49, raking in a sum of $20,988. After this sale, 29,538 common shares of AVDL are directly owned by the insider, with total stake valued at $66,756.

In the transaction dated Aug. 10, 2018, the great number of shares disposed came courtesy the; Hatten Sandra L disposed a total of 6,290 shares at an average price of $4.91, amounting to approximately $30,884. The insider now directly owns 47,410 shares worth $107,147.

Avadel Pharmaceuticals plc (AVDL) Analyst Guide

Several analysts have released their opinion on Avadel Pharmaceuticals plc (NASDAQ:AVDL), with 0 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 3 average brokerage recommendation.